Alternate Nostril Breathing and Blood Pressure: What We Know

Alternate nostril breathing may lower blood pressure, but the best available estimate is too inconsistent to treat as a prescription. A 2024 meta-analysis of six randomized controlled trials, totaling 525 participants, reported average reductions of 7.16 mmHg in systolic pressure and 5.16 mmHg in diastolic pressure. Those numbers would matter clinically if they held up. The problem is that the trials differed so sharply that the pooled average cannot tell you what result to expect from a particular routine, person, or diagnosis.

That still leaves a practical conclusion: slow, structured nasal breathing is a reasonable, free adjunct for someone managing mild hypertension, provided it sits beside—not in place of—medication and established lifestyle treatment.

The headline result is encouraging, not precise

In Nam et al.'s 2024 systematic review and meta-analysis, alternate nostril breathing reduced systolic blood pressure by 7.16 mmHg (95% CI, −7.86 to −6.45) and diastolic pressure by 5.16 mmHg (95% CI, −5.89 to −4.44). All six randomized trials in the quantitative analysis pointed toward lower blood pressure.

The confidence intervals look unusually tidy. They should not reassure you too much. Statistical heterogeneity was extreme: I² was 93% for systolic pressure and 87% for diastolic pressure. In practical terms, the trials were producing very different-sized effects while being summarized under one average. The meta-analysis supports a directional signal—blood pressure tended to fall—but not a dependable claim that the technique lowers systolic pressure by exactly 7.16 mmHg.

The broader review included 14 studies and 1,377 participants, and some interventions embedded alternate nostril breathing within larger yoga programs. That matters because a yoga program can change more than breathing: it may alter stress, activity, attention, and other health behaviors. Those components can affect blood pressure too.

Why slow breathing could affect blood pressure

Alternate nostril breathing, also called Anulom Vilom or Nadi Shodhan pranayama, typically slows breathing to roughly four to six cycles per minute. Slow breathing around this range can synchronize with naturally occurring blood-pressure oscillations and engage the baroreflex, the system that helps regulate heart rate and vascular tone. The proposed result is greater parasympathetic activity and less sympathovascular drive.

This is also the physiological target of device-guided slow breathing. Resperate uses pacing and biofeedback to guide breathing at roughly six to 10 breaths per minute; alternate nostril breathing is a device-free way to practice a similar slow-breathing pattern. That is a mechanistic comparison, not proof that the two approaches work equally well. No head-to-head randomized trial has compared alternate nostril breathing with Resperate.

A 12-week randomized trial in people with mild-to-moderate Parkinson's disease found that Anulom Vilom, used as an adjunct, improved measures of cardiac autonomic balance, including parasympathetic heart-rate-variability indices. Those are physiological markers, not blood-pressure outcomes, and Parkinson's disease can affect autonomic function in ways that limit generalization. Still, the findings fit the proposed pathway.

Other breathing research points in the same direction without proving that nostril alternation itself is the active ingredient. A randomized trial of yoga-based breathing and relaxation in chronic migraine improved heart-rate-variability measures and autonomic regulation. It did not isolate alternate nostril breathing or establish a blood-pressure effect.

The evidence gets weaker when you ask what works for whom

Baseline blood pressure likely changes the size of any benefit. A 2024 systematic review of breathing exercises in hypertensive patients identified baseline blood pressure as a primary moderator: people starting with higher pressure showed larger absolute reductions. Nam et al. pooled hypertensive, prehypertensive, and normotensive participants without a subgroup analysis. That makes the combined estimate less useful for a person with diagnosed hypertension and even less relevant for someone whose blood pressure is already normal.

A 2025 exploratory randomized trial in hypertensive adults tested Nadi Shodhan pranayama as an addition to standard non-drug management. The pranayama group had favorable blood-pressure outcomes. But the intervention was added to diet counseling, exercise recommendations, and other standard measures, so the trial cannot assign the observed change to breathing alone.

The evidence also cannot separate nostril alternation from the broader effects of sitting quietly and deliberately slowing the breath. Participants and investigators cannot realistically be blinded to a breathing technique. Most trials in the meta-analysis were not double-blinded, and no consistent validated sham-breathing control was used. Expectations and extra health-conscious behavior could contribute to the measured effect.

One related breathing trial shows why controls matter

Different yogic breathing practices should not be treated as interchangeable proof. In a randomized trial of bee-humming breathing, 70 people with essential hypertension practiced either five minutes of humming breathing or placebo slow breathing. Compared with the placebo breathing group, humming breathing did not significantly reduce systolic pressure (effect size 2.22 mmHg, 95% CI, −13.20 to 17.64; p=0.77), diastolic pressure (4.54 mmHg, 95% CI, −17.40 to 26.48; p=0.68), or mean pressure after the session. A quiet slow-breathing control may itself have an effect, and an immediate five-minute test answers a different question than a daily practice over weeks.

That result does not refute alternate nostril breathing. It does show why a breathing study needs an active comparison group before anyone credits the distinctive ritual—humming, nostril switching, or a timer—with the whole outcome.

How it fits beside better-established options

Alternate nostril breathing is one possible addition to a blood-pressure plan, not the centerpiece. A 2024 meta-analysis of inspiratory muscle strength training, covering 12 randomized trials and 386 participants, found systolic pressure fell by 7.93 mmHg (95% CI, −12.08 to −3.78) and diastolic pressure by 3.80 mmHg (95% CI, −6.08 to −1.53). Trial-sequential analysis supported the systolic and diastolic findings, although heart-rate-variability results varied considerably.

Resistance training, dietary approaches, and nitrate-rich beetroot juice also have randomized-trial meta-analyses in relevant populations, including a 2024 review of beetroot juice in adults with clinical hypertension. These options do not make breathing irrelevant. They do mean no one should trade established treatment for a nostril-switching routine and call it cardiovascular strategy.

A sensible way to try it

For most people, a conservative protocol is 10 to 20 minutes daily at about five slow breaths per minute. Sit comfortably, breathe gently through the nose, and alternate which nostril you close between breaths. Do not strain, hold your breath aggressively, or turn the practice into a contest with your lungs.

• Use it as an adjunct to prescribed antihypertensive medication, exercise, diet changes, and clinical follow-up.
• Measure blood pressure with a validated home cuff at consistent times if you want to know whether it helps you.
• Discuss persistent readings at or above your clinician's target with a clinician; breathing practice is not treatment for stage 2 hypertension.
• Stop if the technique causes dizziness, panic, or discomfort.

The evidence supports trying alternate nostril breathing as low-risk slow-breathing practice. It does not yet support promising a specific blood-pressure reduction, device equivalence, or a lasting effect after practice stops.

No trial in the meta-analysis tracked participants after the intervention ended, so researchers do not know whether any benefit persists without continued practice. A larger hypertensive-only trial, with standalone alternate nostril breathing, an active sham control, and at least six months of follow-up would answer the questions that the current literature leaves open. Until then, this is a rational free habit with an uncertain dose of benefit—not a replacement for treatment.